Baxter International Inc. (BAX)
- Previous Close
39.65 - Open
39.93 - Bid --
- Ask --
- Day's Range
39.39 - 40.08 - 52 Week Range
31.01 - 50.21 - Volume
2,709,563 - Avg. Volume
3,568,670 - Market Cap (intraday)
20.104B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.15 - Earnings Date May 2, 2024
- Forward Dividend & Yield 1.16 (2.93%)
- Ex-Dividend Date Feb 29, 2024
- 1y Target Est
45.00
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
www.baxter.com60,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: BAX
Performance Overview: BAX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAX
Valuation Measures
Market Cap
20.20B
Enterprise Value
31.37B
Trailing P/E
--
Forward P/E
13.68
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.35
Price/Book (mrq)
2.40
Enterprise Value/Revenue
2.12
Enterprise Value/EBITDA
18.76
Financial Highlights
Profitability and Income Statement
Profit Margin
17.93%
Return on Assets (ttm)
3.34%
Return on Equity (ttm)
-0.96%
Revenue (ttm)
14.81B
Net Income Avi to Common (ttm)
-76M
Diluted EPS (ttm)
-0.15
Balance Sheet and Cash Flow
Total Cash (mrq)
3.19B
Total Debt/Equity (mrq)
169.63%
Levered Free Cash Flow (ttm)
1.7B
Research Analysis: BAX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: BAX
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, obesity drug's effect on dialysis may be muted; looking at the upcoming commercial real estate cycle; and taking the US economic pulse; and Amcor PLC, Sinopharm Group, and Hennes & Mauritz.
Analyst Report: Baxter International Inc.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
RatingBullishPrice TargetAnalyst Report: Baxter International Inc.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
RatingBullishPrice TargetAnalyst Report: Baxter International Inc.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
RatingBullishPrice Target